Khunti, K., Davies, M., Majeed, A., Thorsted, B.L., Wolden, M.L. and Paul, S.K. (2015) Hypoglycemia and Risk of Cardiovascular Disease and All-Cause Mortality in Insulin-Treated People with Type 1 and Type 2 Diabetes: A Cohort Study. Diabetes Care, 38, 316-322.
http://dx.doi.org/10.2337/dc14-0920

has been cited by the following article:

• TITLE: Improved All Cause and Cardiovascular Mortality and Morbidity by Empagliflozin: Too Good to Be True!

  AUTHORS: Udaya M. Kabadi

  KEYWORDS: Review Paper

  JOURNAL NAME: Journal of Diabetes Mellitus, Vol.6 No.2, April 20, 2016

  ABSTRACT: It was interesting to read the recent article regarding the efficacy of Empagliflozin in reducing all cause and cardiovascular mortality [1]. Superficially, the report appears to be very promising. However, the methodology, the results and the conclusions deserve and need further scrutiny and validation for several reasons.